241 related articles for article (PubMed ID: 20230546)
21. A comparison of the EQ-5D-3L and ICECAP-O in an older post-acute patient population relative to the general population.
Couzner L; Crotty M; Norman R; Ratcliffe J
Appl Health Econ Health Policy; 2013 Aug; 11(4):415-25. PubMed ID: 23807538
[TBL] [Abstract][Full Text] [Related]
22. Mapping from the Health Assessment Questionnaire to the EQ-5D: the impact of different algorithms on cost-effectiveness results.
Pennington B; Davis S
Value Health; 2014 Dec; 17(8):762-71. PubMed ID: 25498771
[TBL] [Abstract][Full Text] [Related]
23. Time trade-off derived EQ-5D weights for Australia.
Viney R; Norman R; King MT; Cronin P; Street DJ; Knox S; Ratcliffe J
Value Health; 2011; 14(6):928-36. PubMed ID: 21914515
[TBL] [Abstract][Full Text] [Related]
24. Chinese time trade-off values for EQ-5D health states.
Liu GG; Wu H; Li M; Gao C; Luo N
Value Health; 2014 Jul; 17(5):597-604. PubMed ID: 25128053
[TBL] [Abstract][Full Text] [Related]
25. Assessing utility values in rheumatoid arthritis: a comparison between time trade-off and the EuroQol.
Ariza-Ariza R; Hernández-Cruz B; Carmona L; Dolores Ruiz-Montesinos M; Ballina J; Navarro-Sarabia F;
Arthritis Rheum; 2006 Oct; 55(5):751-6. PubMed ID: 17013822
[TBL] [Abstract][Full Text] [Related]
26. Valuations of epilepsy-specific health states: a comparison of patients with epilepsy and the general population.
Mulhern B; Rowen D; Snape D; Jacoby A; Marson T; Hughes D; Baker G; Brazier J
Epilepsy Behav; 2014 Jul; 36():12-7. PubMed ID: 24836527
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of a cardiovascular disease primary prevention programme in a primary health care setting. Results of the Polish part of the EUROACTION project.
Sović N; Pająk A; Jankowski P; Duenas A; Kawecka-Jaszcz K; Wolfshaut-Wolak R; Stepaniak U; Kawalec P
Kardiol Pol; 2013; 71(7):702-11. PubMed ID: 23907903
[TBL] [Abstract][Full Text] [Related]
28. Health-related quality of life in psoriasis: an analysis of Psocare project patients.
Spandonaro F; Altomare G; Berardesca E; Calzavara-Pinton P; Chimenti S; Girolomoni G; Peserico A; Guerra AP; Vena GA; Polistena B; Ayala F
G Ital Dermatol Venereol; 2011 Jun; 146(3):169-77. PubMed ID: 21566546
[TBL] [Abstract][Full Text] [Related]
29. Mapping from disease-specific measures to health-state utility values in individuals with migraine.
Gillard PJ; Devine B; Varon SF; Liu L; Sullivan SD
Value Health; 2012 May; 15(3):485-94. PubMed ID: 22583459
[TBL] [Abstract][Full Text] [Related]
30. A valuation of infusion therapy to preserve islet function in type 1 diabetes.
Lloyd A; Swinburn P; Boye KS; Curtis B; Sarpong E; Goldsmith K; Bode B; Aronoff S
Value Health; 2010 Aug; 13(5):636-42. PubMed ID: 20712603
[TBL] [Abstract][Full Text] [Related]
31. Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values.
Hernández Alava M; Wailoo AJ; Ara R
Value Health; 2012 May; 15(3):550-61. PubMed ID: 22583466
[TBL] [Abstract][Full Text] [Related]
32. Health state utility values in locally advanced and metastatic breast cancer by treatment line: a systematic review.
Paracha N; Thuresson PO; Moreno SG; MacGilchrist KS
Expert Rev Pharmacoecon Outcomes Res; 2016 Oct; 16(5):549-559. PubMed ID: 27574879
[TBL] [Abstract][Full Text] [Related]
33. Toward a Centralized, Systematic Approach to the Identification, Appraisal, and Use of Health State Utility Values for Reimbursement Decision Making: Introducing the Health Utility Book (HUB).
Xie F; Zoratti M; Chan K; Husereau D; Krahn M; Levine O; Clifford T; Schunemann H; Guyatt G
Med Decis Making; 2019 May; 39(4):370-378. PubMed ID: 30902030
[TBL] [Abstract][Full Text] [Related]
34. Utility values in health technology assessments: a statistician's perspective.
Whately-Smith C; Watkins C; Mann H; Fletcher C; Ducournau P
Pharm Stat; 2014; 13(3):184-95. PubMed ID: 24692364
[TBL] [Abstract][Full Text] [Related]
35. A reference set of Health State Utility Values for gambling problem behaviour, a survey of the Australian general population: implications for future healthcare evaluations.
Moayeri F
Expert Rev Pharmacoecon Outcomes Res; 2020 Feb; 20(1):115-124. PubMed ID: 31003582
[No Abstract] [Full Text] [Related]
36. Estimating EQ-5D utility values for major health behavioural risk factors in England.
Maheswaran H; Petrou S; Rees K; Stranges S
J Epidemiol Community Health; 2013 Feb; 67(2):172-80. PubMed ID: 22844084
[TBL] [Abstract][Full Text] [Related]
37. Elicitation of informed general population health state utility values: a review of the literature.
McTaggart-Cowan H
Value Health; 2011 Dec; 14(8):1153-7. PubMed ID: 22152187
[TBL] [Abstract][Full Text] [Related]
38. Health state utility values among children and adolescents with disabilities: protocol for a systematic review.
Kanya L; Anokye N; Ryan JM
BMJ Open; 2018 Feb; 8(2):e019978. PubMed ID: 29467137
[TBL] [Abstract][Full Text] [Related]
39. The relationship among mental health status (GHQ-12), health related quality of life (EQ-5D) and health-state utilities in a general population.
Serrano-Aguilar P; Ramallo-Fariña Y; Trujillo-Martín Mdel M; Muñoz-Navarro SR; Perestelo-Perez L; de las Cuevas-Castresana C
Epidemiol Psichiatr Soc; 2009; 18(3):229-39. PubMed ID: 20034201
[TBL] [Abstract][Full Text] [Related]
40. Health utility scores in Alzheimer's disease: differences based on calculation with American and Canadian preference weights.
Oremus M; Tarride JE; Clayton N; ; Raina P
Value Health; 2014; 17(1):77-83. PubMed ID: 24438720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
